Use of recombinant granulocyte-macrophage colony-stimulating factor during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia (AML): final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer (EORTC-LCG) and the Dutch Belgian Hemato-Oncology Cooperative Group (HOVON)
Faculty of Medicine and Health Sciences
New York, N.Y.
Blood / American Society of Hematology. - New York, N.Y.
, p. 2952-2961
University of Antwerp